Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Infectious Diseases |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006 |
Resumo: | Several formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections. |
id |
BSID-1_6fbab990d090c61db375bf816a9677ad |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702007000200006 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patientsAmphotericin Bfat emulsioncryptococcal meningitisAIDS patientsSeveral formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections.Brazilian Society of Infectious Diseases2007-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006Brazilian Journal of Infectious Diseases v.11 n.2 2007reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702007000200006info:eu-repo/semantics/openAccessRubio,Fernando GóngoraZanon,Jeferson RodrigoAlmeida,Margarete Teresa Gottardo deGóngora,Delzi Vinha Nunes deeng2007-06-27T00:00:00Zoai:scielo:S1413-86702007000200006Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2007-06-27T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
title |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
spellingShingle |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients Rubio,Fernando Góngora Amphotericin B fat emulsion cryptococcal meningitis AIDS patients |
title_short |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
title_full |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
title_fullStr |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
title_full_unstemmed |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
title_sort |
Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients |
author |
Rubio,Fernando Góngora |
author_facet |
Rubio,Fernando Góngora Zanon,Jeferson Rodrigo Almeida,Margarete Teresa Gottardo de Góngora,Delzi Vinha Nunes de |
author_role |
author |
author2 |
Zanon,Jeferson Rodrigo Almeida,Margarete Teresa Gottardo de Góngora,Delzi Vinha Nunes de |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Rubio,Fernando Góngora Zanon,Jeferson Rodrigo Almeida,Margarete Teresa Gottardo de Góngora,Delzi Vinha Nunes de |
dc.subject.por.fl_str_mv |
Amphotericin B fat emulsion cryptococcal meningitis AIDS patients |
topic |
Amphotericin B fat emulsion cryptococcal meningitis AIDS patients |
description |
Several formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1413-86702007000200006 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.11 n.2 2007 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209239811751936 |